Karuna Therapeutics, Inc., a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that management will present at the following upcoming investor conferences.
Karuna Therapeutics to Present at Upcoming November 2023 Investor Conferences Read More »
Nuvalent, Inc. announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the BMO Virtual BioPharma Spotlight Series: Oncology Day on Wednesday, November 8, 2023, at 1:00 p.m. ET.
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day Read More »
ViroCell Biologics announces that the Company is now able to manufacture and globally export viral vectors from Great Ormond Street Hospital’s state-of-the-art manufacturing facility, the Zayed Centre for Research, for use in clinical trials.
Spexis AG announced that Hernan Levett, currently Chief Financial Officer, has decided to pursue a new career opportunity outside the company.
Spexis Announces Changes to the Executive Committee Read More »
Amsterdam, the Netherlands – argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that members of management will participate in several upcoming investor conferences in November.
argenx to Present at Upcoming November 2023 Investor Conferences Read More »
Apnimed, Inc. announced a new joint venture with Shionogi & Co., Ltd., a leading global research-driven pharmaceutical company based in Japan, to develop novel pharmacologic therapies to treat obstructive sleep apnea and other sleep disorders.
argenx SE announced 20 presentations of clinical trial and real-world data from studies of VYVGART® and VYVGART Hytrulo® in neuromuscular autoimmune disease.
Daewoong Pharmaceutical is pleased to announce its financial results for the third quarter of 2023.
Daewoong Pharmaceutical Reports Third Quarter 2023 Financial Results Read More »
EpimAb Biotherapeutics is excited to announce that the company will present the first-in-human results for EMB-06 in a late-breaking poster presentation at the 2023 Society for Immunotherapy of Cancer Annual Meeting to be held in San Diego, California, from November 3-5.
Antengene Corporation Limited announced that it has presented results from five programs by poster presentation, including two clinical programs on the anti-CD24 monoclonal antibody ATG-031 and the PD-L1/4-1BB bispecific antibody ATG-101.
